MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Phase 3
Completed
Conditions
Pneumonia
Ventilators, Mechanical
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
318
Registration Number
NCT00211016

A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity

Phase 2
Completed
Conditions
Obesity
Binge-Eating Disorder
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
407
Registration Number
NCT00210808

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2
Completed
Conditions
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
186
Registration Number
NCT00210600

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Phase 3
Completed
Conditions
Urinary Tract Infections
Pyelonephritis
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
403
Registration Number
NCT00210990

Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches

Phase 3
Completed
Conditions
Migraine
Headache
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
347
Registration Number
NCT00210821

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Phase 3
Completed
Conditions
Pneumonia
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
240
Registration Number
NCT00211003

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Phase 3
Completed
Conditions
Bacterial Infections and Mycoses
Appendicitis
Cholecystitis
Pancreatitis
Peritonitis
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
478
Registration Number
NCT00210938

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Phase 2
Completed
Conditions
Anemia
Critical Illness
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
60
Registration Number
NCT00210756
© Copyright 2025. All Rights Reserved by MedPath